64 stories found
Numerous companies, including Johnson & Johnson, Wells Fargo, and Gladstone Capital, have released their latest quarterly earnings summaries, provided previews for upcoming financial reports, or declared dividends. These announcements cover a wide spectrum of corporate financial updates.
Johnson & Johnson has announced that it is raising its dividend for the 64th consecutive year.
Johnson & Johnson reported first-quarter profits that surpassed analyst estimates, even as sales of its key drug Stelara fell short of expectations.
Johnson & Johnson is experiencing gains driven by the strong performance and growth of its innovative medicine division.
Royalty Pharma and Johnson & Johnson have finalized a $500 million deal concerning an autoimmune drug, marking a significant collaboration in the pharmaceutical sector.
Jim Cramer highlighted Johnson & Johnson stock's 'free fall' and subsequent rise, noting its resilience despite ongoing lawsuits.
Johnson & Johnson (Vietnam) Co., Ltd. has signed a Memorandum of Understanding with K Hospital, initiating a new phase of collaboration to enhance oncology care services in Vietnam.
Johnson & Johnson's Darzalex has secured approval for its self-administered injectable formulation, marking a significant milestone as the first of its kind for cancer treatment.
A $950 million punitive damages award against Johnson & Johnson (JNJ) has been overturned, though a $16 million talc verdict against the company remains in place.
Jim Cramer noted that Johnson & Johnson's stock should have performed better but struggled to overcome prevailing stagflation theories in the market.
Coloplast has named Gavin Wood, a former executive from Johnson & Johnson, as its new Chief Executive Officer.
Bank of America has increased its price target for Johnson & Johnson (JNJ) following an improved outlook for the company's pipeline.
Johnson & Johnson has launched a new website for direct-to-consumer sales, expanding its reach and sales channels.
An analysis explores whether Johnson & Johnson (JNJ) stock continues to offer value to investors.
This week's notable healthcare headlines highlight developments concerning major companies such as Johnson & Johnson, Masimo, and Bayer.
This article provides a roundup of recent dividend declarations from various companies including Halliburton, AbbVie, Johnson & Johnson, and Delta Air Lines.
Johnson & Johnson is reportedly exploring a potential $20 billion sale of its orthopedics unit.
An analysis compares Verizon and Johnson & Johnson to determine which dividend hike winner is the better investment.
Financial commentator Jim Cramer shares his latest opinions on several major stocks, including Procter & Gamble, Norfolk Southern, and Johnson & Johnson, offering insights into their performance and market standing.
Johnson & Johnson updated its 2026 outlook, projecting $11.30-$11.50 EPS and a $100.2 billion sales midpoint, with an overall target of $100 billion in annual revenue.
Jim Cramer advises investors to consider buying Johnson & Johnson stock if it experiences a significant dip in value.
Johnson & Johnson reported sales that surpassed expectations, primarily attributed to strong growth in its cancer medicine segment.
Several prominent companies, including Johnson & Johnson, Netflix, TSMC, Goldman Sachs, Citigroup, JPMorgan Chase, Bank of America, and PepsiCo, are scheduled to release their earnings reports in the coming week. Investors will be closely watching these announcements for insights into corporate performance and economic trends.
Billionaire investor Ray Dalio is reportedly bullish on Oracle Corporation (ORCL) stock.
The Zacks Analyst Blog features an analysis of several major corporations, including Duke Energy, Entergy, Constellation Brands, Coca-Cola, and Johnson & Johnson.
A key opponent in Johnson & Johnson's talc litigation, who had challenged the company's bankruptcy strategy, has been ousted from their position, as confirmed by new reports from the Wall Street Journal.
Johnson & Johnson (JNJ) has made significant progress in its bladder cancer treatment, reporting an impressive 89% response rate in recent trials. This development offers new hope for patients.
Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots.
Citi has increased its price target for Johnson & Johnson (JNJ) from $250 to $274, providing insights into the reasons for the upgrade.
Johnson & Johnson units are reportedly set to pay $65 million in a Tracleer antitrust class action settlement, according to Reuters.
Johnson & Johnson subsidiaries have reached a $65 million settlement to resolve an antitrust lawsuit concerning the drug Tracleer.
Gavin Wood afløser 1. maj Lars Rasmussen som ny øverste chef for Coloplast. Wood kommer fra Johnson & Johnson.
Bayer has filed a lawsuit against Johnson & Johnson concerning claims related to a prostate cancer drug.
Bloomberg reports that Johnson & Johnson is exploring a potential significant asset sale.
An analysis suggests that Johnson & Johnson is a highly recommended healthcare stock for long-term investment.
Johnson & Johnson is reportedly exploring the sale of its orthopedics business, a move that could reshape its medical device portfolio.
Johnson & Johnson is exploring the sale of its orthopedics unit, a move that could fetch more than $20 billion.
AC Immune announced that its partner Johnson & Johnson has paused enrollment in a mid-stage clinical trial for an Alzheimer’s drug.
Shares of Johnson & Johnson rose about 1% on Tuesday, with analysts discussing how the stock can build on its strong start.
Several major companies, including Citigroup, BlackRock, and Johnson & Johnson, have reported strong first-quarter earnings that exceeded analyst estimates. These results highlight robust performance in various sectors, from financial markets to healthcare.
An article provides a preview of what to expect from Johnson & Johnson's first-quarter earnings report. Analysts are anticipating key financial metrics and business segment performance.
An analysis highlights an $18 billion market reason to consider investing in a 147-year-old dividend-paying stock. The article suggests this long-standing company offers a compelling investment opportunity.
An investment analysis compares Coca-Cola and Johnson & Johnson stocks to determine which offers more reliability for a $10,000 investment.
Johnson & Johnson (JNJ) is experiencing positive performance, driven by its robust growth pipeline and strong presence across several key therapeutic areas.
Royalty Pharma has entered into a $500 million research and development funding collaboration with Johnson & Johnson, specifically partnering to develop new treatments for autoimmune diseases.
A key opponent in Johnson & Johnson's talc litigation, who had challenged the company's bankruptcy strategy, has been ousted from their position.
Investors and analysts are anticipating Johnson & Johnson's upcoming earnings release, with details expected to provide insights into the company's financial performance.
Financial commentator Jim Cramer highlighted Skyworks Solutions' high yield but stated he doesn't invest in tech for yield.
An analyst has issued a bullish forecast for Johnson & Johnson, predicting its stock price could climb to $280, indicating strong confidence in the company's future performance.
Bank of America has increased its price target for Johnson & Johnson (JNJ), citing the company's strong pipeline growth as the primary reason.
US FDA approves Johnson & Johnson's blood cancer drug after speedy review Reuters
An article provides reasons to confidently hold Johnson & Johnson stock even during a potential market crash.
Johnson & Johnson announced plans to invest $1 billion in a new manufacturing plant in Pennsylvania, as part of a broader push for US manufacturing.
Johnson & Johnson is highlighted as a 'Dividend King' stock that could serve as a stable anchor for a millionaire retirement portfolio due to its consistent dividend payouts.
The FDA has granted Breakthrough Therapy Designation to Johnson & Johnson's cancer drug, JNJ-73841937, for the treatment of advanced head and neck cancer.
Bloomberg News reports that Johnson & Johnson is considering the sale of its orthopedics unit, a move that could be valued at $20 billion.
Johnson & Johnson plans to construct a new $1 billion cell and gene therapy manufacturing facility in Pennsylvania, expanding its production capabilities.
Johnson & Johnson has secured approval for monthly dosing of its drug Rybrevant Faspro, offering a new treatment option.